Phase 1/2 × Carboplatin × Lymphoid × Clear all
NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Eisai Inc.

Phase 1/2 Completed
41 enrolled
NCT00601718 2017-05-25

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

University of Washington

Phase 1/2 Completed
29 enrolled 10 charts
NCT00003406 2013-03-26

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
30 enrolled